Updates are available Correction dated 2026-01-07
Click to view Correction: https://doi.org/10.1038/s41380-025-03442-x
-
Authors
Lemke, Johannes R. https://orcid.org/0000-0002-4435-6610
Eoli, Andrea
Krey, Ilona
Popp, Bernt
Strehlow, Vincent
Wittekind, Dirk A.
Vuorinen, Anna-Leena https://orcid.org/0000-0002-5658-1305
Aldhalaan, Hesham M.
Baer, Sarah
de Saint Martin, Anne
Hammer, Trine B.
Herman, Isabella
Hornemann, Frauke
Ingebrigtsen, Trine
Lederer, Damien
Lesca, Gaetan https://orcid.org/0000-0001-7691-9492
Marafie, Dana
Mathot, Mikael
Rosenfeld, Jill A.
Møller, Rikke S. https://orcid.org/0000-0002-9664-1448
Schelhaas, Helenius J.
Stillman, Chelsey
Orsini, Alessandro
Patel, Anup D.
Piard, Juliette https://orcid.org/0000-0001-5244-5325
Veggiotti, Pierangelo
Vlaskamp, Danique R. M.
Weckhuysen, Sarah https://orcid.org/0000-0003-2878-1147
Traynelis, Stephen F. https://orcid.org/0000-0002-3750-9615
Benke, Tim A.
Heyne, Henrike O.
Syrbe, Steffen https://orcid.org/0000-0003-2543-4844
-
Funding
Funding for this research was provided by:
Simons Foundation (732132)
Simons Foundation (732132)
U.S. Department of Health & Human Services | National Institutes of Health (NS111619)
Deutsche Forschungsgemeinschaft (516649954)
- License Information
-
More Information
Article History
Received: 15 November 2024
Revised: 5 August 2025
Accepted: 18 September 2025
First Online: 14 October 2025
Change Date: 22 December 2025
Change Type: Update
Change Details: The original online version of this article was revised: An error was identified in the Methods section of the original article. The last words in the last line of the section Control Cohort incorrectly referred to “psychiatric disorders” at the end of the paragraph. This was a mistake; the correct term is “psychotic disorders.” The original article has been corrected.
Change Date: 7 January 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41380-025-03442-x
Competing interests
: JRL, SFT and TAB are members of the SAB for the GRIN2B Foundation and the CureGRIN Foundation as well as consultants for GRIN Therapeutics. SFT is on the SAB for Eurmentis Therapeutics and Neurocrine Biosciences, and on the BOD of NeurOp Inc. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical testing completed at Baylor Genetics Laboratories.
: We confirm that all methods performed were in accordance with the declaration of Helsinki. This study has been approved by the ethics committees of the University of Leipzig, Germany (224/16-ek, 402/16-ek, 379/21-ek) and the University of Colorado (COMIRB 16-1520). Informed consent was obtained from all participants
